Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 10,492 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Non Small Cell Lung Cancer, Small-cell Lung Cancer, Mesothelioma, Cognitive Behavioral Therapy
Interventions: Run-In Sessions 1-5, RCT Transitions Program Sessions 1-5, RCT Control Session; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sepsis
Interventions: Observation; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
Interventions: Lenalidomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Cancer, Residual Disease
Interventions: Niraparib, Radiation Therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: JNJ-64042056, Placebo; Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more

Conditions: Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions: Bupropion, Behavioral activation therapy, Placebo, Clinical Management; Drug · Behavioral · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Stony Brook, New York • Dallas, Texas • Seattle, Washington

Conditions: Cerebellar Ataxia
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Elkins Park, Pennsylvania

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Telaglenastat Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Tampa, Florida • Rochester, Minnesota + 2 more

Conditions: Skin Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 1,889 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2026
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more

Conditions: Epilepsy Intractable
Interventions: Direct electrical stimulation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more

Conditions: Brain Blood Flow, Healthy
Interventions: MRI; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 69 Years
Enrollment: 80 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Knee Osteoarthritis
Interventions: DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Smoking Cessation, Tobacco
Interventions: smartphone applications; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Cancer
Interventions: ESTRING, Replens, Vagifem; Drug
Lead sponsor: Polly A. Niravath, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Back Pain
Interventions: Erchonia® Trident; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Carcinoma
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: MPS IVA, MPS VI
Interventions: Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 10 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Oakland, California

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more

Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 493
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more

Conditions: Heart Failure
Interventions: OPTIMIZER Smart System; Device
Lead sponsor: Impulse Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more

Conditions: Depression, Treatment Resistant Depression, Mood Disorders, Bipolar Disorder, Mental Disorders, Bipolar and Related Disorders
Interventions: Observational Study; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 10 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity
Interventions: Standard behavioral treatment, Standard behavioral treatment plus relationship skills training; Behavioral
Lead sponsor: Becky Marquez; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Cardiovascular Disease, Alcohol Use Disorder, HIV Risk, Substance Use Disorders
Interventions: Navigation, compensation, and personalization; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 35 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance

Dynamics of Organ Damage and Immune Exhaustion During Sepsis

Lenalidomide for Adult Histiocyte Disorders

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Combination of Novel Therapies for CKD Comorbid Depression

Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

Memory Retrieval and Encoding Investigated by Neural Stimulation

Blood Vessel Anatomy and Blood Flow Regulation

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

LLLT to Reduce Low Back Pain

Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy

Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression

Family Functioning in Obesity Treatment for Mexican Americans

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery